Hutchmed (China) announced that the results of the ESLIM-01 Phase III trial of Selpinnib (HMPL-523) for adult primary immune thrombocytopenia have been published in The Lancet Haematology. Further details of the study, including subgroup results, were also presented in the form of an oral report and two posters at the European Hematology Association (EHA) Annual Meeting on June 14, 2024.

Selpinnib is a novel, highly selective, oral spleen tyrosine kinase (Syk) inhibitor used to treat hematologic malignancies and immune diseases. The results of the ESLIM-01 trial suggest that Selpinnib has the potential to be a treatment option for immune thrombocytopenia patients who have received at least one prior therapy.

In addition, the safety of Selpinnib in the ESLIM-01 study was consistent with previous clinical studies. Most treatment-emergent adverse events (TEAEs) were mild or moderate (Grade 1 or 2). In patients receiving Selpinnib treatment, 25.4% experienced Grade 3 TEAEs or higher, compared to 24.2% in the placebo group. Selpinnib also significantly improved patients' physical functioning and energy/fatigue-related quality of life (p <0.05).